STAA

STAAR Surgical Company 10-K Summary (Fiscal Year Ended Dec 31, 2010)

Business Context and Reporting Period

Company: STAAR Surgical Company (Nasdaq: STAA)
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: STAAR designs, develops, manufactures, and sells implantable lenses for ophthalmic surgery, specifically Intraocular Lenses (IOLs) for cataracts and Implantable Collamer Lenses (ICLs) for refractive surgery. The company operates as a single segment with significant international exposure (73% of sales outside the U.S.).
Key Event: On March 2, 2010, the company divested its German distribution subsidiary, Domilens GmbH, which is reported as discontinued operations.

Key Financial Metrics

Note: Net Income for 2010 includes a $4.17 million gain from discontinued operations (Domilens divestiture). Loss from continuing operations was $4.11 million.

Material Changes vs. Prior Period

• Revenue Growth: Driven by a 15.5% increase in ICL sales (to $24.3M) and a 4.8% increase in IOL sales (to $27.6M). International sales grew significantly in India, China, and Korea, offsetting a 4.2% decline in U.S. ICL sales due to the economic recession.
• Margin Expansion: Gross margin improved to 63.8% due to the expiration of a royalty-bearing patent, a shift toward higher-margin ICL products, and the removal of low-margin third-party products following the Domilens divestiture.
• Debt Elimination: The company repaid its $5 million Broadwood Promissory Note and redeemed all 1.7 million shares of Series A Preferred Stock ($6.8 million) in the second quarter of 2010, leaving no material indebtedness.
• Legal Settlement: The company settled outstanding litigation for $4.0 million in the second quarter, utilizing funds from the Domilens sale and a court deposit release.

Guidance, Outlook, and Risks

Management Commentary:

• Profitability Goal: Management aims to achieve sustainable profitability in 2011, though the company did not achieve net income from continuing operations in 2010 due to increased sales/marketing investments and severance costs.
• R&D Focus: Planned R&D investment is approximately 10% of sales for 2011. Key initiatives include the U.S. launch of silicone preloaded injectors, development of a Collamer Toric IOL, and presbyopic IOLs.
• Regulatory Status: The FDA approval for the Toric ICL (TICL) remains pending. The application was under review following a deficiency letter response in August 2010. Approval is critical for U.S. refractive growth.

Risks and Contingencies:

• Regulatory Delays: Continued delays in TICL approval could hinder U.S. market expansion.
• Economic Sensitivity: Refractive surgery is elective and sensitive to economic downturns; U.S. private sector demand remains weak.
• Competition: Intense competition from larger firms (Alcon, Abbott, Bausch & Lomb) with greater resources.
• Single-Sourcing: Reliance on a single internal facility for proprietary Collamer raw material creates supply chain risk.
• Pension Obligations: Defined benefit plans in Switzerland and Japan are underfunded by approximately $2.6 million.

Investor Verification Checklist

• Continuing Operations Profitability: Verify if the company can achieve net income from continuing operations in 2011 without the one-time gain from discontinued operations.
• TICL FDA Approval: Monitor the status of the Toric ICL PMA supplement, as this is a primary growth driver for the U.S. market.
• Cash Flow Sustainability: Assess whether operating cash flow can remain positive given the $4.4M outflow in 2010 (driven by litigation settlement) and the need to fund R&D and marketing.
• Inventory Levels: Review inventory days on hand (116 days in 2010) to ensure no significant write-downs are required for the complex ICL inventory mix.
• U.S. ICL Recovery: Confirm if U.S. private sector ICL sales have rebounded from the 4.2% decline seen in 2010.